Safety and effectiveness of growth hormone therapy in infants with Prader-Willi syndrome younger than 2 years: a prospective study.

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this clinical trial publication.

A prospective study was conducted to assess the safety of GH therapy in infants younger than 2 years of age with PWS.

Why It Was Studied

Background There is little evidence of the effects of early treatment with growth hormone (GH) in infants with Prader-Willi syndrome (PWS).

The median age at start of GH treatment was 9.6 months (interquartile range [IQR] 9.0-18.3 months).

Who Took Part

The study group was 14 patients.

PubMed indexes the participants as infants, both men and women.

How the Study Was Run

Changes in height standard deviation score (SDS), body mass index (BMI) SDS and subcapsular and tricipital skinfolds in the follow-up period were evaluated with a mixed-model regression analysis using the Package R.

What Was Measured

The subject headings attached to it are Body Composition, Body Height, Body Mass Index, Child Development, Cognition, Human Growth Hormone and Motor Activity.

Author keywords: Prader-Willi syndrome.

What This Means in Plain Language

This is a clinical trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 14 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2019 (Journal of pediatric endocrinology & metabolism : JPEM), a journal based in Germany.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.